International Medical Case Reports Journal

Dovepress
open access to scientific and medical research

CASE SERIES

International Medical Case Reports Journal downloaded from https://www.dovepress.com/ on 22-Jun-2022
For personal use only.

Open Access Full Text Article

Magnetic resonance imaging findings and
neurodevelopmental outcomes in neonates
with urea-cycle defects
This article was published in the following Dove Press journal:
International Medical Case Reports Journal
18 August 2013
Number of times this article has been viewed

Anna Catherine Gunz 1
Karen Choong 2
Murray Potter 3
Elka Miller 4
Division of Critical Care,
Department of Pediatrics, University
of Ottawa, Children’s Hospital
of Eastern Ontario, Ottawa, ON,
Canada; 2Department of Pediatrics,
3
Department of Pathology and
Molecular Medicine, McMaster
University, Hamilton, ON, Canada;
4
Diagnostic Imaging Department,
Children’s Hospital of Eastern
Ontario, Ottawa, ON, Canada
1

Abstract: The urea-cycle functions to facilitate ammonia excretion, a disruption of which results
in the accumulation of toxic metabolites. The neurological outcome of neonatal-onset urea-cycle
defects (UCDs) is poor, and there are no good predictors of prognosis beyond ammonia levels at
presentation. The role of neuroimaging in the prognosis of neonatal-onset UCDs is unclear. We
describe the magnetic resonance imaging (MRI) findings of two patients with neonatal-onset UCDs
(argininosuccinic aciduria and citrullinemia) at presentation and at 2-year follow-up, and present a
review of the literature on neuroimaging in this age-group. We observed two potentially significant
distinct patterns of cerebral involvement on MRI: (1) a central and focal pattern of involvement
limited to the basal ganglia, perirolandic regions, and internal capsule; and (2) diffuse involvement
of the cerebral cortex, internal capsule, basal ganglia, and variably thalami and brain stem. Patients
with more diffuse findings tended to have higher serum glutamine peaks and worse neurological
outcomes, while those with central involvement, aggressive acute management, and early liver
transplantation tended to have better outcomes. We propose that MRI imaging of the brain may have
prognostic value following presentation with neonatal UCDs, particularly in identifying patients at
risk for poor outcome. The role and timing of follow-up neuroimaging is currently unclear. Further
collaborative studies are necessary to evaluate whether patterns of MRI findings vary with specific
UCD subtypes, and are predictive of clinical outcomes in neonatal UCDs.
Keywords: hyperammonemia, amino acid metabolism, inborn error, metabolism, inborn errors,
infant, newborn, magnetic resonance imaging
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Urea-cycle defects (UCDs) result in hyperammonemia and the accumulation of
glutamine and various toxic metabolites. Neonatal-onset UCDs are associated with
poor neurodevelopmental outcome, often resulting in cerebral palsy and developmental
delay.1–3 Left untreated, these disorders result in progressive seizures, coma, and death.
The use of magnetic resonance imaging (MRI) is increasingly reported in neonatal
hyperammonemia;4–7 however, the association with neurological outcome is unclear.
We present two cases of neonatal-onset UCD, their brain MRI findings, and
neurodevelopmental outcome at 2 years. We reviewed the literature and summarize the
reported patterns of MRI findings in this population, and hypothesize their significance in
relation to subtypes of UCD, biochemical markers, and neurodevelopmental outcome.

Case 1: argininosuccinic aciduria
A full-term female infant presented on her second day of life (DOL) with seizures,
hypovolemic shock, multi-organ system dysfunction, peak serum ammonia in the acute phase
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of 1,092 µmol/L (normal ,80 µmol/L), and peak glutamine in
the acute phase of 1,728 µmol/L (normal 376–709 µmol/L,
Table 1). Ammonia-lowering agents (sodium benzoate, sodium
phenylacetate, and l-arginine) were promptly initiated; she
had approximately 12 hours of hemodialysis. Her ammonia
normalized within 36 hours. Quantitative plasma amino acid
analysis confirmed a diagnosis of the UCD, argininosuccinic
aciduria (argininosuccinic acid 853 µmol/L, citrulline
292 µmol/L [normal 10–24 µmol/L], urine argininosuccinic acid
58,617 µmol/L). At 20 months, she was noted to have moderate
language and motor delays (Table 2).
MRI was performed on DOL 8 (Figure 1A and B). T1- and
T2-weighted images showed increased signal intensity of
the globus pallidus, caudate nucleus, internal capsule, and
bifrontal corona radiata, extending into the perirolandic
regions. There was no restricted diffusion. Follow-up imaging
at 25 months (Table 3) revealed residual signal change of the
caudate nucleus and globus pallidus, with globus pallidus
volume loss (Figure 1C).

hemodialysis. Her ammonia level normalized within
24 hours. The quantitative amino acid profile yielded a
diagnosis of citrullinemia (citrulline 4,074 µmol/L, ornithine
25 µmol/L [normal 48–211 µmol/L], arginine 62 µmol/L
[normal 6–140 µmol/L], no urine argininosuccinic acid). At
27 months, she displayed mild motor and language delays,
microcephaly and failure to thrive (less than third percentile
for head circumference, height, and weight; Table 2).
MRI on DOL 11 (Figure 2A and B) demonstrated
diffuse restricted diffusion with predominance posteriorly,
sparing the superior frontal lobe and parts of the temporal
lobe. There was involvement of the globus pallidus,
internal capsule, corpus callosum, thalami, and cerebral
peduncles. At 24 months of age, repeat MRI (Table 3)
showed increased signal of the periventricular white matter
with associated posterior white-matter volume loss
and ventricular enlargement (Figure 2C).

Case 2: citrullinemia

Discussion
Patterns of brain MRI findings
and urea-cycle defects

This full-term female infant presented on DOL 7 with
seizures, peak serum ammonia of 1,345 µmol/L, and peak
serum glutamine of 3,055 µmol/L (Table 1). Ammonialowering agents were initiated; she had 4 hours of

A review of the literature found four case reports of brain
MRIs of eight neonates after acute presentation with
neonatal-onset hyperammonemia, summarized in Table 1.4–7
Based on these cases, we interpreted two patterns of cerebral

Table 1 Location of cerebral involvement, as indicated by magnetic resonance imaging (MRI), of cases of neonatal-onset urea-cycle
defects in the subacute phase of recovery after presentation, as well as timing of presentation and MRI, peak serum ammonia, and
glutamine levels
Diagnosis

Age at
diagnosis

Age at
MRI

Peak
ammonia*
(μmol/L)

Peak
glutamine*
(μmol/L)

Pattern of
cerebral
involvement

Perirolandic

Insula

Patient 1
Patient 2

ASA
Citrullinemia

DOL 2
DOL 7

DOL 8
DOL 11

1,092
1,345

1,728
3,055

Central
Diffuse

+
+

Patient 34

CPS I

DOL 2

2 weeks

978

1,710

Central

+

+

Patient 44
Patient 54
Patient 65

OTCD
CPS 1
Citrullinemia

DOL 4
DOL 2
DOL 5

2 weeks
2 weeks
DOL 8

1,420
1,700
2,083

1,268
3,067

Central
Central
Diffuse

+
+
+

+
+
+

Patient 77

OTCD

DOL 2

DOL 12

952

6,491

Diffuse

+

Patient 86
Patient 96
Patient 106
Patient 116

OTCD
OTCD
Citrullinemia
OTCD

DOL 2
DOL 1
DOL 2
DOL 1**

DOL 5
DOL 8
DOL 8
DOL 5

3,035
2,652
2,196
2,684

2,883
3,308
3,809
3,398

Diffuse
Diffuse
Diffuse
Central

+
+
+

+
+
+
+

Notes: *Peak concentration during initial acute presentation; **recognized within 8 hours and corrected rapidly in 24 hours (patients 1, 2, and 3 recognized belatedly).
Patient 1 and 2 are Case 1 and 2 of this study, respectively.
Abbreviations: ASA, argininosuccinic aciduria; CPS I, carbamoyl phosphate synthetase I deficiency; CN, caudate nucleus; GB, globus pallidus; OTCD, ornithine
transcarbamylase deficiency; DOL, day of life; MOD, multiorgan dysfunction; N/A, not applicable.
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involvement on MRI: diffuse and central/focal. The “diffuse”
pattern consists of extensive involvement of the cerebral
cortex (particularly the posterior cortices excluding the
superior frontal and medial temporal lobes), basal ganglia,
and in some cases, thalami and brain stem; the “central”
pattern consists of signal changes limited to the basal ganglia,
perirolandic region, and internal capsule.
The diffuse pattern of cerebral involvement was more
commonly associated with high peak serum glutamine
levels (.2,800 µmol/L) than serum ammonia levels during
the acute phase of presentation. In addition, we note that
the diffuse pattern of cerebral involvement was common to
cases of citrullinemia. While our patient with argininosuccinic aciduria presented with multiorgan dysfunction, which
may have contributed to the pattern of cerebral involvement
noted on MRI, the pattern of involvement was similar to
other patients with UCD who did not present with multiorgan
dysfunction. There was insufficient information provided in
the literature to demonstrate a relationship between duration
of hyperammonemia and patterns of cerebral involvement.

Neuropathophysiology of urea-cycle
defects and findings on neuroimaging
Authors have described a correlation between severity of
outcome and duration and/or peak concentration of ammonia.8

Basal
ganglia

Internal
capsule

+ (GB&CN)
+ (GB&CN)

+
+

Temporal

Current hypotheses suggest the direct effect of hyperammonemia on the brain causes more injury than cerebral
edema from its osmotically active toxic metabolite, glutamine, alone.8 In order to detoxify ammonia, glutamine
synthetase (GS) catalyzes the condensation of ammonia
and glutamate to form glutamine in astrocytes.8,9 However,
if the GS-enzyme pathway becomes saturated, ammonia
will accumulate. Elevated cerebral ammonia has a number
of neurophysiological effects, including increased cerebral
edema from impaired glucose oxidation and subsequent
lactate accumulation,10 loss of cerebral autoregulation,10
effects on neurotransmitters, synaptic transmission,
nitric oxide synthesis, 9,11 and stimulation of N-methyld-aspartate receptors, which may downregulate GS.9 In
our study, the demonstrated association between more
diffuse cerebral involvement and high glutamine peaks
builds upon the findings of Bireley et al, 6 and seems
contrary to what is understood about the pathogenesis of
hyperammonemia.
The bulk of the literature dedicated to understanding the
neuropathogenesis of UCDs focuses on the neurotoxic effects
of glutamine and hyperammonemia. However, there may be
additional neurotoxic effects of specific metabolites of different subtypes of UCD, such as with arginase deficiency3 and
citrullinemia.12 This may contribute to the diffuse pattern of

Parietal–
occipital

Frontal

Thalami

Corpus
callosum

Brain
stem

+

+

+

+

+

+ (GB)
+ (GB)
+ (GB&CN)
+ (GB)

+

+

+

+

+

+

+

+

+
+

+/+
+/-

+
+
+

+
+
+
+
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+
+

+
+

+

+
+
+

Restricted areas in
diffusion-weighted
imaging
None
Diffuse, sparing superior frontal
and parts of temporal lobes
Unknown

MODs
No MODs

Unknown
Unknown
Diffuse, corresponds with
T2 signal changes
Diffuse, as described, including
optic radiata, cerebral peduncle,
scattered through cortex
(particularly posterior)
Diffuse, as described
Diffuse, as described
Diffuse, as described
Limited, as described

No MODs
No MODs
No MODs
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Table 2 Neurodevelopmental and long-term outcome of patients with a diffuse or central pattern of cerebral involvement, as well as
peak serum ammonia and glutamine levels after acute presentation by subtype of urea-cycle defect
Diagnosis

Peak ammonia*
(μmol/L)

Peak glutamine*
(μmol/L)

Pattern of cerebral
involvement
(acute phase)

Further episodes of
hyperammonemia
prior to follow-up

Patient 1
Patient 2
Patient 34

ASA
Citrullinemia
CPS 1

1,092
1,345
978

1,728
3,055
1,710

Localized
Diffuse
Localized

Yes**
No
Yes

Patient 44
Patient 54
Patient 65

OTCD
CPS I
Citrullinemia

1,420
1,700
2,083

1,268
3,067

Localized
Localized
Diffuse

Unknown
Unknown
No

Patient 77

OTCD

952

6,491

Diffuse

Unknown

Patient 86
Patient 96
Patient 106
Patient 116

OTCD
OTCD
Citrullinemia
OTCD

3,035
2,652
2,196
2,684

2,883
3,308
3,809
3,398

Diffuse
Diffuse
Diffuse
Localized

Unknown
N/A
N/A
No

Notes: *Peak concentration during initial acute presentation; **two severe episodes at 18 and 26 months old, respectively, and 1 minor episode at 28 months old; ***where
applicable. Patient 1 and 2 are Case 1 and 2 of this study, respectively.
Abbreviations: ASA, argininosuccinic aciduria; CPS I, carbamoyl phosphate synthetase I deficiency; DOL, day of life; OTCD, ornithine transcarbamylase deficiency; WOLS,
withdrawal of life support.

cerebral involvement noted in all patients in this series with
a diagnosis of citrullinemia.

Neuroimaging and neurodevelopmental
outcome
The neurodevelopmental outcomes of patients were
graded according to the schema introduced by Bireley
et al6 (Table 2). Patients with mild outcomes had transient
symptomatology during periods of hyperammonemia
that completely resolved. Those with moderate outcomes
had persistent neurocognitive delays or neurological
abnormalities. Patients with severe outcomes had profound
neurocognitive delays or severe spastic quadriplegia.
Generally, patients with more extensive cortical involvement
had more severe neurodevelopmental outcomes (Table 2).
An exception was our citrullinemia case (patient 2). In
contrast, children with central cerebral involvement had
variable neurodevelopmental outcomes. The subtype of UCD
was not predictive of neurodevelopmental outcome.
That more extensive cerebral involvement noted on
MRI translates into more severe neurodevelopmental outcome follows. However, the fact that not all patients with
diffuse involvement had severe outcomes (ie, patient 2),
and that patients with a central pattern of cerebral involvement or similar subtypes of UCD had variable outcomes,
reflects the complexity of the neuropathophysiology of
these disorders. Important contributing factors may include
cumulative patient-specific factors, such as the duration
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of hyperammonemia on presentation, chronic exposure to
mild hyperammonemia, number of subsequent episodes of
severe hyperammonemia (patient 2 had no subsequent episodes), and exposure to other toxic UCD metabolites.
Early and agg ressive management of patients
with neonatal-onset UCD, regardless of subtype, may
modify the neurocognitive outcome. The patients with
better neurological outcomes (patients 44 and 116), had
liver transplants at an early age, early and aggressive
management (patient 4 4), or no repeated episodes of
hyperammonemia (patients 2 and 116). The patients with
more severe neurodevelopmental outcomes (patients 34
and 54) had repeated episodes of hyperammonemia and/or
transplantation at a later age.
Patients with brain-stem and thalamic involvement
tended to have worse neurodevelopmental outcomes, with
the exception of patient 2. While Bireley et al6 hypothesized
that thalamic injury may be partially caused by secondary
anoxic insult from hemodynamic instability, it may simply
represent more severe cerebral disease (our patient with
thalamic involvement remained hemodynamically stable). In
contrast to Bireley et al’s6 findings, restricted diffusion was
not consistently associated with worse outcome.

Pattern of cerebral involvement
demonstrated in follow-up imaging
The degree of signal resolution and development of
cerebral volume loss demonstrated by follow-up MRIs
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Neurodevelopmental
sequelae

Neurodevelopmental
outcome

Moderate
Moderate
Severe

Moderate language and motor delay
Microcephaly, failure to thrive, mild language and motor delay
Truncal hypotonia, appendicular hypertonia, choreoathetosis,
global neurodevelopmental delay
Nonoral food intake, age-appropriate development
Moderate neurodevelopmental delays
4 months old: microcephaly, severe neurodevelopmental
delay, hypotonia, head lag, hyperreflexia
DOL 89: microcephaly, no head control, suck and swallow
uncontrolled, hyperreflexia, clonus bilaterally
“Severe quadriparetic cerebral palsy with minimal development”
“Neurological devastation”
“Severely depressed neurological function”
Hypotonia and mild motor delays at 1 year old

Moderate
Moderate
Severe
Severe
Severe
Severe
Severe
Moderate

varied (Table 3). The consistent findings of signal changes
and volume loss in the basal ganglia and posterior cerebral
cortex (including parieto-occipital encephalomalacia in
severe cases) reinforce the importance of these structures in
the pathogenesis of this disease.
From the information presented, it is diff icult to
demonstrate a clear relationship between the pattern of
cerebral involvement noted on MRI after acute presentation
and long-term follow-up. This is due to the variability in the
timing and indication of follow-up imaging in this series, as
well as the small number of patients with each subtype of
UCD who underwent later imaging. In addition, it is unclear
to what extent the pattern of cerebral involvement seen in later
imaging reflects subsequent episodes of hyperammonemia.

Age at
death***

Cause of
death***

Age at liver
transplant***

8 months
6 weeks
7 months

15 months
DOL 15
DOL 20

Unknown
WOLS
WOLS
11 weeks

For example, the later imaging of patient 8 was the only
follow-up imaging that demonstrated restricted diffusion.
However, this MRI was done 2 days after the patient presented
with an episode of hyperammonemia, and thus likely reflects
this acute process. Overall, we question the clinical utility of
follow-up imaging, as it may not change clinical management
when there are no further episodes of hyperammonemia.
Limitations of this review include the small sample size,
which reflects the rarity of this disease, and lack of access
to full case images and developmental assessments from the
literature. In addition, for each case, the number of days that
an MRI was done after acute presentation varied from 3 days
to 2 weeks, which may affect the degree of diffusivity noted
on the respective diffusion-weighted imaging.13,14

Figure 1 Axial T1- (A) and T2-weighted magnetic resonance images (B) of case 1 show increased signal intensity of the internal capsule, globus pallidus (arrows) and caudate
nucleus (stars), bifrontal corona radiata, extending into the perirolandic regions (not shown). Axial T2-weighted magnetic resonance image (C) of case 1 done at follow-up
at 25 months reveals residual signal change of the caudate nucleus (stars) and globus pallidus, with decreased size of the globus pallidus (arrows).
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CPS I

Citrullinemia

OTCD

OTCD

Patient 34

Patient 65

Patient 77

Patient 86

No

Yes

Unknown

No

Yes

No

Yes*

Further episodes of
hyperammonemia
prior to follow-up

2 days after
hyperammonemic
episode
Unknown

Unknown

After 2 significant
episodes of
hyperammonemia
Unknown

Routine follow-up

Routine follow-up

Indication for
follow-up MRI

6 months

11 months

3 months

4 months

7 months

24 months

25 months

Age at
follow-up
MRI

Moderate

Moderate

Global

Extensive

Diffuse atrophy;
VL mostly BG

Diffuse posterior

GP only

Volume loss

Thalami

Bilateral

Insula

Parietooccipital
leukomalacia

Restricted diffusion

T2 increased signal
GP and CN
T2 increased signal
T2 increased
GP and CN
signal
T2 prolongation GP
and CN; T1 shortening
of putamen

Basal ganglia

Resolution of previously
restricted diffusion

Subcortical cysts (especially
occipital); ulegyric changes
T1 high signal cerebral
white matter
Restricted diffusion
temporal and occipital

Slightly delayed myelination

Other

Notes: *Peak concentration during initial acute presentation; **recognized within 8 hours and corrected rapidly in 24 hours (patients 1, 2, and 3 recognized belatedly); Patient 1 and 2 are Case 1 and 2 of this study, respectively.
Abbreviations: ASA, argininosuccinic aciduria; BG, basal ganglia; CPS I, carbamoyl phosphate synthetase I deficiency; CN, caudate nucleus; DOL, day of life; GP, globus pallidus ; OTCD, ornithine transcarbamylase deficiency; VL, volume loss.

OTCD

Citrullinemia

Patient 2

Patient 116

ASA

Patient 1

Diagnosis

Table 3 Location of cerebral involvement demonstrated by follow-up magnetic resonance imaging (MRI) by subtype of urea-cycle defect, age, and imaging indication, also including
number of subsequent episodes of hyperammonemia between presentation and follow-up imaging
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Figure 2 Axial apparent diffusion coefficient (A and B) magnetic resonance images of case 2 show diffuse restricted diffusion with predominance posteriorly (arrow), sparing
the superior frontal lobe and parts of the temporal lobe. There was involvement of the globus pallidus, internal capsule, cerebral peduncles (short arrows), corpus callosum
(star), and thalami (triangles). Axial T2-weighed magnetic resonance image (C) of case 2 at 24 months of age shows increased signal of the periventricular white matter
(arrows) with associated posterior white-matter volume loss and enlargement of the ventricular system.

Conclusion
For clinicians involved in the acute management of neonates
presenting with UCDs, prognostication is extremely important,
as some parents will elect to withdraw life-sustaining therapy
if the projected neurodevelopmental outcome is devastating.
We hypothesize that the pattern of cerebral involvement seen
in the subacute phase of recovery from hyperammonemia on
MRI, as well as early biomarkers such as glutamine, may have
a role in predicting neurodevelopmental outcome in these
children. If MRI reveals a central pattern of involvement, strict
and aggressive management and early hepatic transplantation
may help preserve neurological function. However, given the
rarity of this disease, scarcity of published case reports, and
inconsistency in neurodevelopmental reporting and follow-up
presented in the literature, clinical decision-making based
on neuroimaging results alone should be done with caution.
Large clinical trials are necessary to delineate more clearly the
predictive value of neuroimaging after acute presentation, as
well as the relative importance of aggressive therapeutics, in
the long-term neurodevelopmental outcome of these children.
The clinical utility of follow-up imaging is unclear.
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